The past decade has shown tremendous advances in the care of patients with lung cancer. With improved survival comes the opportunity for patients to become survivors who advocate for research by attending conferences, forming relationships with physicians and care providers, and lending their voices through committee involvement and speaking opportunities. The IASLC offers several opportunities to help transform patients into patient research advocates.
Patient Advocacy Spotlights
IASLC Urges Congress to Fund the Lung Cancer Research Program
The International Association for the Study of Lung Cancer is one of 55 groups that have signed on to urge Congress to allocate $60 million to the Lung Cancer Research Program within the Congressionally Directed Medical Research Program (CDMRP) in the Fiscal Year 2023 Department of Defense appropriations bill.
Advocates at Work
Dr. D. Ross Camidge on Teliso-V Monotherpay in patients with previously treated C-Met+ Advanced NSCLC
Jill Feldman Discusses the IASLC Language Guide
Ivy Elkins Discusses Real-World Treatment for Patients with EGFR-Positive Lung Cancer
Ivy Elkins on Pembrolizumab in Combination with Platinum-Based Chemo in Recurrent EGFR/ALK+ NSCLC
Jill Feldman on Improving Tobacco Cessation Among Individuals Undergoing Lung Cancer Screening
Amy C. Moore, PhD Discusses the Epical Trial
Angus Pratt Discusses Medical Assistance in Dying (MAID) in Lung Cancer
Dr. Upal Basu Roy Discusses Data from the NADIM Trial and from the National Cancer Database regarding the addition of surgery to Chemoradiation of the Chemotherapy
We proudly partner with 13+ advocacy organizations to advance the care of patients with lung cancer in patient-driven ways that focus on quality of care and quality of life.
Image
Image
Image
Image
Image
Image
Image
Image
Image
Image
Image
Image
